Nephrotic syndrome medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 9: Line 9:


  IV albumin, although generally not recommended for hypoalbuminemia due to its transient effects, has been shown to have synergistic effects with diuretics for an increased delivery of protein-bound diuretics to sites of action.<ref name="pmid18497417">{{cite journal| author=Hull RP, Goldsmith DJ| title=Nephrotic syndrome in adults. | journal=BMJ | year= 2008 | volume= 336 | issue= 7654 | pages= 1185-9 | pmid=18497417 | doi=10.1136/bmj.39576.709711.80 | pmc=PMC2394708 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18497417 }} </ref> Nonetheless, albumin is still not widely recommended, and its risks may at times outweigh the benefits because it is associated with anaphylaxis, hypertension, and pulmonary edema.<ref name="pmid18497417">{{cite journal| author=Hull RP, Goldsmith DJ| title=Nephrotic syndrome in adults. | journal=BMJ | year= 2008 | volume= 336 | issue= 7654 | pages= 1185-9 | pmid=18497417 | doi=10.1136/bmj.39576.709711.80 | pmc=PMC2394708 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18497417 }} </ref>
  IV albumin, although generally not recommended for hypoalbuminemia due to its transient effects, has been shown to have synergistic effects with diuretics for an increased delivery of protein-bound diuretics to sites of action.<ref name="pmid18497417">{{cite journal| author=Hull RP, Goldsmith DJ| title=Nephrotic syndrome in adults. | journal=BMJ | year= 2008 | volume= 336 | issue= 7654 | pages= 1185-9 | pmid=18497417 | doi=10.1136/bmj.39576.709711.80 | pmc=PMC2394708 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18497417 }} </ref> Nonetheless, albumin is still not widely recommended, and its risks may at times outweigh the benefits because it is associated with anaphylaxis, hypertension, and pulmonary edema.<ref name="pmid18497417">{{cite journal| author=Hull RP, Goldsmith DJ| title=Nephrotic syndrome in adults. | journal=BMJ | year= 2008 | volume= 336 | issue= 7654 | pages= 1185-9 | pmid=18497417 | doi=10.1136/bmj.39576.709711.80 | pmc=PMC2394708 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18497417 }} </ref>
Treatment includes:
Treatment includes:
===General Measures (Supportive)===
===General Measures (Supportive)===



Revision as of 09:26, 17 November 2013

Nephrotic Syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Nephrotic syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X-Ray

Echocardiography or Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Nephrotic syndrome medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Nephrotic syndrome medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Nephrotic syndrome medical therapy

CDC on Nephrotic syndrome medical therapy

Nephrotic syndrome medical therapy in the news

Blogs on Nephrotic syndrome medical therapy

Directions to Hospitals Treating Nephrotic syndrome

Risk calculators and risk factors for Nephrotic syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Medical Therapy

Treatment of Edema

There are currently no guidelines for the management of edema associated with nephrotic syndrome. The slow reversal of edema is important at a rate of 0.5-1 kg daily to prevent electrolyte disturbances, hypovention, ischemic acute tubular necrosis, and hemoconcentration associated with aggressive diuretic therapy.[1][1]

IV Loop diuretics, like furosemide or bumetanide[2], are mostly used as first line diuretics. The use of oral medications is generally avoided due to poor absorption in cases of interstinal edema and due to presence of hypoalbuminemia[1] Addition of thiazide-type diuretics, metolazone, or potassium-sparing diuretics are also reasonable options.[2] There are currently no guidelines to outline the appropriate dosages and drug selection.

IV albumin, although generally not recommended for hypoalbuminemia due to its transient effects, has been shown to have synergistic effects with diuretics for an increased delivery of protein-bound diuretics to sites of action.[1] Nonetheless, albumin is still not widely recommended, and its risks may at times outweigh the benefits because it is associated with anaphylaxis, hypertension, and pulmonary edema.[1]

Treatment includes:

General Measures (Supportive)

  • Monitoring and maintaining euvolemia (the correct amount of fluid in the body)
    • Monitoring urine output, BP regularly
    • Fluid restrict to 1L
  • Monitoring kidney function
    • Do EUCs daily and calculating GFR
  • Prevent and treat any complications [see below]
  • Albumin infusions are generally not used because their effect lasts only transiently.

Specific Treatment of Underlying Cause

  • Standard ISKDC Regime for first episode: Prednisolone -60 mg/m2 /day in 3 divided doses for 4 weeks followed by 40mg/m2/day in a single dose on every alternate day for 4 weeks.
  • Relapses by prednisolone 2mg/kg/day till urine becomes negetive for protein. Then,1.5mg/kg/day for 4 weeks.
  • Achieving stricter blood glucose control if diabetic
  • BP control. ACE inhibitors are the drug of choice. Independent of their blood pressure lowering effect, they have been shown to decrease protein loss.

Dietary Recommendations

  • Limit high protein animal foods to 1 oz per meal (preferably lean cuts of meat, fish, and poultry)
  • Limit high phosphorous foods such as cheese, cooked dried beans and peas, nut butters, soy, tofu, and yogurt, including cokes and colas.
  • Limit high potassium vegetables and fruits such as artichokes, avocado, bamboo shoots, beets, brussels sprouts, chard, greens (such as beet and collards), kohlrabi, okra, parsnips, potatoes, pumpkin, rutabagas, spinach, sweet potatoes, tomatoes, tomato juice, tomato sauce, wax beens, winter squash, yams. Fruits include, apricots, bananas, dates, honey dew, nectarines, orange juice, oranges, prune juice.
  • Avoid saturated fats and eat unsaturated fats in moderation.
  • Eat low-fat desserts only.
  • Monitor fluid intake which includes all fluids and foods that are liquid at room temperature.

References

  1. 1.0 1.1 1.2 1.3 1.4 Hull RP, Goldsmith DJ (2008). "Nephrotic syndrome in adults". BMJ. 336 (7654): 1185–9. doi:10.1136/bmj.39576.709711.80. PMC 2394708. PMID 18497417.
  2. 2.0 2.1 Brater DC (1998). "Diuretic therapy". N Engl J Med. 339 (6): 387–95. doi:10.1056/NEJM199808063390607. PMID 9691107.
  3. Hodson E, Willis N, Craig J (2007). "Corticosteroid therapy for nephrotic syndrome in children". Cochrane database of systematic reviews (Online) (4): CD001533. doi:10.1002/14651858.CD001533.pub4. PMID 17943754.

Template:WH Template:WS